|
1
|
Yuan J, Li J, Yang L, Lv Y, Wang C, Jin Z, Ni X, Xia H. Development and validation of a novel reporter gene assay for determination of recombinant human thrombopoietin. Int Immunopharmacol 2021; 99:107982. [PMID: 34333355 DOI: 10.1016/j.intimp.2021.107982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 07/09/2021] [Accepted: 07/10/2021] [Indexed: 11/15/2022]
Abstract
Recombinant human thrombopoietin (rhTPO) was approved by the National Medical Products Administration in 2010 for the treatment of thrombocytopenia in patients with immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia. Nevertheless, no method for determining rhTPO bioactivity has been recorded in different national/regional pharmacopoeia. Novel methods for lot release and stability testing are needed that are simpler, quicker, and more accurate. Here, we developed a novel reporter gene assay (RGA) for rhTPO bioassay with Ba/F3 cell lines that stably expressed human TPO receptor and luciferase reporter driven by sis-inducible element, gamma response region, and gamma-interferon activated sequence. During careful optimization, the RGA method demonstrated high performance characteristics. According to the International Council for Harmonization Q2 (R1) guidelines and the Chinese Pharmacopoeia 2020 edition, the validation results demonstrated that this method is highly time-saving, sensitive, and robust for research, development, manufacture, and quality control of rhTPO.
Collapse
Affiliation(s)
- Jie Yuan
- School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, Liaoning 110016, China; Shenyang Sunshine Pharmaceutical CO., Ltd, 1(st) 3, 10(th) Road, Economic and Technological Development Zone, Shenyang, Liaoning 110027, China
| | - Jia Li
- Shenyang Sunshine Pharmaceutical CO., Ltd, 1(st) 3, 10(th) Road, Economic and Technological Development Zone, Shenyang, Liaoning 110027, China
| | - Lihua Yang
- School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, Liaoning 110016, China; Shenyang Sunshine Pharmaceutical CO., Ltd, 1(st) 3, 10(th) Road, Economic and Technological Development Zone, Shenyang, Liaoning 110027, China
| | - Yunying Lv
- School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, Liaoning 110016, China; Shenyang Sunshine Pharmaceutical CO., Ltd, 1(st) 3, 10(th) Road, Economic and Technological Development Zone, Shenyang, Liaoning 110027, China
| | - Chao Wang
- Shenyang Sunshine Pharmaceutical CO., Ltd, 1(st) 3, 10(th) Road, Economic and Technological Development Zone, Shenyang, Liaoning 110027, China
| | - Zheng Jin
- Shenyang Sunshine Pharmaceutical CO., Ltd, 1(st) 3, 10(th) Road, Economic and Technological Development Zone, Shenyang, Liaoning 110027, China
| | - Xianpu Ni
- School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, Liaoning 110016, China.
| | - Huanzhang Xia
- School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, Liaoning 110016, China.
| |
Collapse
|